Fihr Chaudhary, Wismmy Lee, Tony Escander, Devendra K Agrawal
{"title":"探索特应性皮炎的复杂性:病理生理学机制与治疗方法。","authors":"Fihr Chaudhary, Wismmy Lee, Tony Escander, Devendra K Agrawal","doi":"10.26502/jbb.2642-91280155","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a prevalent inflammatory skin condition impacting both children and adults globally, with a prevalence of 15-30%. It ranks as the most prevalent skin disorder based on disability-adjusted life-years by the World Health Organization. It presents with symptoms like skin irritation, redness, dryness, itchiness, and vesicular blisters and commonly coexists with other atopic symptoms like allergic rhinitis, asthma, and food allergies. The pathophysiology involves a complex interplay of genetic predispositions, immunological dysfunctions, and environmental factors leading to tissue inflammation and disrupted skin barrier integrity. Alopecia areata is characterized by nonscarring hair loss and shares correlations with AD including a higher prevalence of atopic diseases, shared intracellular mechanisms involving the JAK-STAT pathway, and potential treatment overlap such as dupilumab. These correlations could direct new areas of research and increased insight for both diseases. Treatment of AD requires a personalized approach due to its complex, multifactorial nature integrating nonpharmacological interventions like skin hydration and trigger avoidance as well as topical and systemic approaches, if necessary, with topical corticosteroids being the first line for flares; long term corticosteroid use poses risk for adverse effects like skin atrophy. Severe cases may require systemic treatments or phototherapy. Future treatment prospects include targeting the dysbiotic microbiome and identifying biomarkers for tailored therapeutic strategies, emphasizing the importance of personalized medicine in optimizing AD management.</p>","PeriodicalId":518002,"journal":{"name":"Journal of biotechnology and biomedicine","volume":"7 3","pages":"314-328"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309089/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches.\",\"authors\":\"Fihr Chaudhary, Wismmy Lee, Tony Escander, Devendra K Agrawal\",\"doi\":\"10.26502/jbb.2642-91280155\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Atopic dermatitis (AD) is a prevalent inflammatory skin condition impacting both children and adults globally, with a prevalence of 15-30%. It ranks as the most prevalent skin disorder based on disability-adjusted life-years by the World Health Organization. It presents with symptoms like skin irritation, redness, dryness, itchiness, and vesicular blisters and commonly coexists with other atopic symptoms like allergic rhinitis, asthma, and food allergies. The pathophysiology involves a complex interplay of genetic predispositions, immunological dysfunctions, and environmental factors leading to tissue inflammation and disrupted skin barrier integrity. Alopecia areata is characterized by nonscarring hair loss and shares correlations with AD including a higher prevalence of atopic diseases, shared intracellular mechanisms involving the JAK-STAT pathway, and potential treatment overlap such as dupilumab. These correlations could direct new areas of research and increased insight for both diseases. Treatment of AD requires a personalized approach due to its complex, multifactorial nature integrating nonpharmacological interventions like skin hydration and trigger avoidance as well as topical and systemic approaches, if necessary, with topical corticosteroids being the first line for flares; long term corticosteroid use poses risk for adverse effects like skin atrophy. Severe cases may require systemic treatments or phototherapy. Future treatment prospects include targeting the dysbiotic microbiome and identifying biomarkers for tailored therapeutic strategies, emphasizing the importance of personalized medicine in optimizing AD management.</p>\",\"PeriodicalId\":518002,\"journal\":{\"name\":\"Journal of biotechnology and biomedicine\",\"volume\":\"7 3\",\"pages\":\"314-328\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309089/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biotechnology and biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/jbb.2642-91280155\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biotechnology and biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/jbb.2642-91280155","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
特应性皮炎(AD)是一种普遍存在的炎症性皮肤病,影响着全球的儿童和成年人,发病率高达 15-30%。根据世界卫生组织对残疾调整生命年的计算,特应性皮炎是发病率最高的皮肤疾病。它表现为皮肤刺激、发红、干燥、瘙痒和水疱等症状,通常与过敏性鼻炎、哮喘和食物过敏等其他特应性症状并存。病理生理学涉及遗传倾向、免疫功能障碍和环境因素的复杂相互作用,导致组织炎症和皮肤屏障完整性破坏。斑秃以非瘢痕性脱发为特征,与注意力缺失症具有共同的相关性,包括特应性疾病的高发病率、涉及 JAK-STAT 通路的共同细胞内机制以及 dupilumab 等潜在的治疗重叠。这些相关性可能会引导新的研究领域,提高对这两种疾病的认识。AD 的治疗需要个性化的方法,因为它具有复杂、多因素的性质,需要整合非药物干预措施,如皮肤保湿和避免诱发因素,必要时还需要局部和全身治疗,局部皮质类固醇激素是治疗复发的一线药物;长期使用皮质类固醇激素会带来皮肤萎缩等不良反应的风险。严重病例可能需要全身治疗或光疗。未来的治疗前景包括以菌群失调的微生物组为靶点,确定生物标志物以制定有针对性的治疗策略,这强调了个性化医疗在优化 AD 管理中的重要性。
Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches.
Atopic dermatitis (AD) is a prevalent inflammatory skin condition impacting both children and adults globally, with a prevalence of 15-30%. It ranks as the most prevalent skin disorder based on disability-adjusted life-years by the World Health Organization. It presents with symptoms like skin irritation, redness, dryness, itchiness, and vesicular blisters and commonly coexists with other atopic symptoms like allergic rhinitis, asthma, and food allergies. The pathophysiology involves a complex interplay of genetic predispositions, immunological dysfunctions, and environmental factors leading to tissue inflammation and disrupted skin barrier integrity. Alopecia areata is characterized by nonscarring hair loss and shares correlations with AD including a higher prevalence of atopic diseases, shared intracellular mechanisms involving the JAK-STAT pathway, and potential treatment overlap such as dupilumab. These correlations could direct new areas of research and increased insight for both diseases. Treatment of AD requires a personalized approach due to its complex, multifactorial nature integrating nonpharmacological interventions like skin hydration and trigger avoidance as well as topical and systemic approaches, if necessary, with topical corticosteroids being the first line for flares; long term corticosteroid use poses risk for adverse effects like skin atrophy. Severe cases may require systemic treatments or phototherapy. Future treatment prospects include targeting the dysbiotic microbiome and identifying biomarkers for tailored therapeutic strategies, emphasizing the importance of personalized medicine in optimizing AD management.